In a more recent systematic review and meta-analysis,
Singh and colleagues [18] included 22 studies; of which
13 assessed α-blockers, 6 assessed nifedipine, and 3
assessed both drugs against control. In the pooled analysis
of 16 studies using α-blockers (n = 1,235), those receiving
active treatment were 59% more likely to pass
the stone, with a baseline stone passage rate of 50% in
the control group. The incidence of mild adverse effects